Everything below concerns c-Met signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
There is not enough specimen for the lab tests ordered to be performed. In the case of Vacutainers or other tubes with pre-added anticoagulant, the amount of blood invacuated into the tube at the time of phlebotomy was insufficient to attain the correct blood:anticoagulant ratio. This can cause false results in assays such as coagulation assays (causing falsely increased clotting times) or blood cell differentials (causing a false increase in poikilocytes, particularly burr cells.) In either case, the most common and feasible way to correct the problem is to simply recollect the specimen. Quantity not sufficient implies that the final volume of diluent is not sufficient for molecular testing.
Levorphanol, sold under the brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. It is the levorotatory enantiomer of the compound racemorphan. Its dextrorotatory counterpart is dextrorphan. It was first described in Germany in 1946. The drug has been in medical use in the United States since 1953.
In men, blockade of the AR by bicalutamide in the pituitary gland and hypothalamus prevents the negative feedback of androgens on the hypothalamic–pituitary–gonadal (HPG) axis, resulting in an increase in luteinizing hormone (LH) secretion and levels. Follicle-stimulating hormone (FSH) levels, in contrast, remain essentially unchanged. The increase in LH levels leads to an elevation in androgen and estrogen levels. At a dosage of 150 mg/day, bicalutamide has been found to increase testosterone levels by about 1.5- to 2-fold (59–97% increase) and estradiol levels by about 1.5- to 2.5-fold (65–146% increase). However, there is variability in these increases, and in one clinical trial, the highest testosterone concentration that occurred with 50 mg/day bicalutamide monotherapy was 2,306 ng/dL, which was five times the normal average level of testosterone in men. Levels of DHT are also increased to a lesser extent (by 24–30%), and concentrations of sex hormone-binding globulin (SHBG) and prolactin increase as well (by 8–42% and 40–65%, respectively) secondary to the increase in estradiol levels. The estradiol concentrations produced in men by bicalutamide monotherapy are said to approximate the low-normal estradiol levels of a premenopausal woman, while testosterone levels generally remain in the high end of the normal male range and rarely exceed it.
Sources: en.wikipedia.org
According to The Economist, "All this makes the most sense if the principal intent is to rattle Mr Maduro, give succour to Venezuela's opposition or even stir an uprising within the Venezuelan armed forces—encouraged perhaps by that recently doubled reward." Experts speaking to Reuters and the BBC described the deployment as gunboat diplomacy and Trump administration sources stated a likely goal was to pressure the Maduro administration. James G. Stavridis, a former US Navy admiral, characterized the strike and other US military activity around the same time as gunboat diplomacy intended to demonstrate the vulnerability of Venezuelan oil rigs and materiel. He wrote that drug interdiction was likely not the sole reason for the increased US military activity. The New York Times reported that a group of officials, led by US National Security Advisor and Secretary of State Marco Rubio, was pushing for a military campaign that would drive Maduro from power. Members of Venezuela's opposition told the New York Times they have coordinated with the Trump administration on a plan for the first hundred hours after Maduro's deposition. PBS News reported that Trump was using the military to counter cartels he blamed for trafficking fentanyl and other illicit drugs into the US and for fuelling violence in American cities, stating that the government had "not signaled any planned land incursion"—similarly, The Guardian stated that "many experts are skeptical the US is planning a military intervention" in Venezuela.
Once the peptide chain is synthesized, it still must be modified. Post-translational modifications can occur before protein folding or after. Common biological methods of modifying peptide chains after translation include methylation, phosphorylation, and disulfide bond formation. Methylation often occurs to arginine or lysine and involves adding a methyl group to a nitrogen (replacing a hydrogen). The R groups on these amino acids can be methylated multiple times as long as the bonds to nitrogen does not exceed 4. Methylation reduces the ability of these amino acids to form hydrogen bonds so arginine and lysine that are methylated have different properties than their standard counterparts. Phosphorylation often occurs to serine, threonine, and tyrosine and involves replacing a hydrogen on the alcohol group at the terminus of the R group with a phosphate group. This adds a negative charge on the R groups and will thus change how the amino acids behave in comparison to their standard counterparts. Disulfide bond formation is the creation of disulfide bridges (covalent bonds) between two cysteine amino acids in a chain which adds stability to the folded structure.
=== Electrolyte balance === Cortisol increases glomerular filtration rate, and renal plasma flow from the kidneys thus increasing phosphate excretion, as well as increasing sodium and water retention and potassium excretion by acting on mineralocorticoid receptors. It also increases sodium and water absorption and potassium excretion in the intestines.
== Viscoelasticity == Viscoelasticity is the phenomena of time-dependent strain exhibited by amorphous materials such as polymers or glasses. The viscoelasticity of materials depend on the viscosity and can be mechanically modelled using mechanical elements known as springs and dashpots. In turn, constitutive equations can relate the mechanical interpretation of viscoelasticity to the materials properties and strain rate.
Sources: en.wikipedia.org
==== List of P-CABs in the markets (First year of approval for clinical use) ==== Revaprazan (2006) Vonoprazan (2014) Tegoprazan (2018) Fexuprazan (2021) Keverprazan (2023/China) Zastaprazan (2024/South Korea)
=== Procedures === Section 316 of the Criminal Procedure Code states that the death penalty in Singapore is to be conducted by hanging. Judicial hangings always take place shortly before dawn on a Friday and are conducted by the long drop method. The Singapore government has affirmed its choice of execution by hanging in favour of other methods. It is a normal practice for everyone present in the courtroom to stand and remain silent before the death sentence is passed. The judge will then proceed to announce the death sentence on the accused, who has been found guilty and convicted of the capital offence. The condemned will be given notice at least four days before execution. In the case of foreigners sentenced to death, their families and diplomatic missions or embassies will be given one to two weeks' notice.
This abnormal chromosome was dubbed the Philadelphia chromosome - as both scientists were doing their research in Philadelphia, Pennsylvania. Thirteen years later, with the development of more advanced techniques, the abnormal chromosome was shown by Janet Rowley to be the result of a translocation of chromosomes 9 and 22. Identification of the Philadelphia chromosome by cytogenetics is diagnostic for CML. More than 780 leukemias and hundreds of solid tumors (lung, prostate, kidney, etc.) are now characterized by an acquired chromosomal abnormality, whose prognostic value is crucial. The identification of these chromosomal abnormalities has led to the discovery of a very large number of "cancer genes" (or oncogenes). The increasing knowledge of these cancer genes now allows the development of targeted therapies, which transforms the prospects of patient survival. Thus, cytogenetics has had and continues to have an essential role in the progress of cancer understanding. Large databases (Atlas of Genetics and Cytogenetics in Oncology and Haematology, COSMIC cancer database, Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer) allow researchers and clinicians to have the necessary corpus for their work in this field.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.